Evaluating therapeutic effects of omega-3 fatty acids on anemia and nutritional status in hemodialysis patients with depressio
- Conditions
- Condition 1: Anemia. Condition 2: Nutritional Status. Condition 3: Depression. Condition 4: Hemodialysis.Anaemia in other chronic diseases classified elsewhereProtein-energy malnutrition of moderate and mild degreeDepressive episodeExtracorporeal dialysisD63.8*
- Registration Number
- IRCT201202203043N5
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Age more than 16 years old; Thrice weekly hemodialysis from the last three months (at least); The patient's ability to understand and sign the consent form; Use of biocompatible hemodialysis membrane; Proper functioning of arteriovenus fistula or indwelling catheter; Beck depression score equal to or more than 16; Post-dialysis body mass index between 20 and 30
Pregnancy; Active, uncontrolled or severe chronic inflammatory disease (autoimmune diseases, active connective tissue diseases,
malignancy, AIDS, hepatic and pulmonary diseases); Chronic infection or acute infection in a recent month; Life expectancy of less than 4 months; Asthma or Chronic obstructive pulmonary disease; Other concurrent Psychiatric disorders; Hypothyroidism; Hemoglubinopathies and other causes of anemia (other than iron deficiency); Simultaneous participation in other trials (Drug or Supplemental); History of medical (like MI or Strock) or surgical illness in the last three months; Malabsorption syndrome; Bleeding disorders (including coagulopathy) or high risk for bleeding; Diet change in a recent month; Consumption of omega-3 supplements in the past 3 months; Intolerance or allergy to fish oil; Use of drugs effective on inflammatory factors (like corticosteroides or other immunosuppressives,
Non-steroidal antiinflammatory drugs, contraceptives, Pentoxifylline) in the past 6 weeks; Concurrent use of antidepressants, antipsychotics, antiepileptics (other than gabapentin), methyldopa, cimetidine and serotonergic agents (like triptans, tramadol, tryptophan and linezolid); Warfarin therapy
; Alcohol abuse and other materials that cause dependency
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method